I can extract side effects

The licensing cooperation (License-in and License-out) of pharmaceutical companies is mainly drug patent licensing.

Among all technical fields, the pharmaceutical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign pharmaceutical companies also runs through the entire process of drug research and development.

In order to develop products, patents must be paralleled or even advanced, and finally market profits can be realized through the monopoly of drug patents.

The basic principle of the patent application strategy is that product patents should be completed in the early stage, especially the core patents related to compounds, so that comprehensive pharmacology and toxicology research can be carried out in the later stage. Method patents and use patents can be applied for in the later stages of new drug development.

In the discovery stage of active new compounds, patent applications mainly include compound patents (general formula compounds, specific compounds), which are the most valuable patents among new drug patents.

With the study of pharmacology and toxicology, patent applications at this stage began to establish peripheral patents, including crystal form patents, active compound salts, esters, isomers, water or solvation patents, etc.

At this point, a patent pool for new compounds begins to take shape.

In the clinical stage, with the deepening of clinical trials and the accumulation of experimental data, patent applications at this stage often include composition patents, various dosage form patents, process patents and use patents, etc.

After the new drug is successfully marketed, in order to further expand the exclusive rights of the patent and prolong the life cycle of the new drug, the patent applications at this stage mainly focus on new composition patents, new dosage form patents, and new use patents.

The above are common patent application strategies at different research stages. There are often overlaps in the actual patent application process. For example, process patents for new compounds can be applied for in preclinical research, clinical research and after marketing. Generally speaking, it is a long-term and dynamic process.

Therefore, Weikang immediately applied for the patent of the new drug compound after he successfully tested the drug, and continued to apply for a series of composition patents in the subsequent clinical stage. The patent application after the listing is still under preparation. The drug approval process is progressing steadily.

Only with this series of combined patent pools for new drugs can it cooperate with other companies for authorization.

Wei Kang carefully looked at the latest cooperation plans sent by Pfizer, Bayer and Johnson \u0026 Johnson after communication.

The strength of these three companies is quite equal, and the proposals proposed are also the best conditions among the multinational giants.

Several other companies either have enough anticancer drugs themselves, or have recently acquired new drug companies, or have undergone asset replacement and business adjustments, and cannot offer more favorable conditions for the time being.

After Bayer's buyout price of 10 billion euros spread, both Pfizer and Johnson \u0026 Johnson updated their cooperation plans and added the buyout price. Although it is not as good as Bayer's, other terms are also more favorable.

He analyzed the relevant materials of these three companies and gained some general understanding.

Bayer really wants to buy out this prescription, so the cooperation plan they proposed is more about spending money.

But Andre from Pfizer secretly revealed to Wei Kang some information that only the inside of the giant knew.

Bayer is also developing a new broad-spectrum anti-cancer drug. It has achieved some results, but the clinical effect is not satisfactory, so they are so eager to buy out the prescription, maybe they want to buy it back and analyze it. Develop this product by itself instead of in-depth cooperation with Sanqing.

Johnson \u0026 Johnson's anti-cancer drug product line is not large, but its products are highly competitive. Because an anti-cancer drug for the treatment of soft tissue tumors developed with a huge amount of money was rejected by the Eagle Country FDA for 6 years, they are now in urgent need of a powerful star product to seize the market, so they are interested in Sanqing’s broad-spectrum anti-cancer drug The desire is also very strong.

As for Pfizer's anti-tumor product line is very rich, and there is no shortage of new drugs, but in some therapeutic areas, their products rank low and are not competitive enough. Now relying on only one or two blockbuster products to compete with other pharmaceutical companies will be very unfavorable in the long run, so it is imperative to win heavy products such as broad-spectrum anticancer drugs, and never give up.

The conclusion is that although Johnson \u0026 Johnson and Pfizer are both powerful, they have their own shortcomings. Overall, Pfizer is weaker and more sincere in long-term cooperation.

Think about it, too, Pfizer has a wide product line, but it is not approved, so when selling medicines, for the sake of sales, it is definitely more willing to sell Sanqing's medicines.

Johnson \u0026 Johnson is currently frustrated, and their own drugs are also very strong. If their own anti-cancer drugs can be launched, they may not be able to develop the market for Sanqing.

As for Bayer, in Wei Kang's mind, he was silently out of the game.

Wei Kang frowned and continued to analyze the authorized cooperation plans of the two companies.

Johnson \u0026 Johnson's plan is: an upfront payment of US$500 million, cumulative development and commercial milestone payments of no more than US$3 billion, and gradient royalties based on global net sales. The total transaction amount is expected to be US$3.5 billion.

Pfizer's plan is: $500 million down payment, and is eligible to receive up to $2 billion in payments after reaching registration milestones, $500 million in payments after reaching cumulative sales milestones, and future sales in authorized territories.

At first glance, the two plans seem to have little difference in amount, and Johnson \u0026 Johnson even gave a little more money.

However, Johnson \u0026 Johnson subsequently gave gradient royalties on global net sales, while Pfizer provided sales shares in authorized regions.

In fact, Wei Kang mainly wants to sell medicines in the Eagle Country and other developed countries, because he can't get involved in these places, and Huaxia's companies are also easy to target.

But there are still many developing countries in the third world on this planet. Huaxia's companies are relatively strong in these places, and he doesn't want to give up most of the market easily.

Pfizer is not so greedy in comparison, and only agrees to sell it in the developed countries involved in the authorization. The two parties will jointly develop the market in these countries, and Pfizer will be responsible for the registration application and start commercial activities after approval.

In addition, Sanqing Pharmaceutical Co., Ltd. can jointly sell products in other developed countries other than Eagle Country and share sales revenue, and part of the operating funds will be provided by Pfizer.

Therefore, which one's plan is better, the result is ready to come out.

Of course, this is also based on the fact that Sanqing has ambitions for the global market. If Sanqing only wants to collect money and has no intention of developing the market with partners, then Johnson \u0026 Johnson’s plan is also a good choice. You only need to lie down and collect money. Can.

Wei Kang then looked at the list of abandoned prescriptions attached to the cooperation plans of various pharmaceutical companies.

This is why Pfizer completely impressed Weikang.

Johnson \u0026 Johnson is similar to other pharmaceutical companies. There are always more than a dozen discarded prescriptions attached, ranging from antineoplastic drugs, AIDS treatment, antithrombotic, and even wound care prescriptions.

Moreover, according to Wei Kang's requirements, the side effects that have been discovered and detailed data are marked.

But Weikang guessed that they should have concealed some side effects, because some medicines have not serious side effects, and they were still abolished.

Of course, there is another possibility, that is, the effect of the drug treatment is too poor, or even ineffective, so it was discarded.

This kind of prescription is useless for others, but it can turn waste into treasure in Wei Kang's hands.

As long as the toxicology test and human tolerance pass, even if the original research and development direction has no effect, Weikang can extract new special drugs from the side effects.

However, there are also many drugs with relatively weak side effects, such as irritation to internal organs. Although some emetics and diarrhea drugs can also be extracted, the market for these drugs is not large, and the effect is not important. There are also many types of existing drugs. Can't make much money.

Only the kind of medicine that can treat fatal diseases is the real gold mine that can make pharmaceutical companies make a fortune.

From these discarded prescriptions, we can also see the main research and development directions of major pharmaceutical companies.

Each pharmaceutical company has a major investment in anticancer drugs, and of course they also target different fields.

Such as blood cancer, lung cancer, lymphoma, melanoma, and so on.

There are also many abandoned prescriptions in other research and development directions, which basically cover all aspects related to human organs.

Wei Kang was dazzled by these prescriptions, and there were quite some side effects that made him feel excited.

He decided to have a good talk with these pharmaceutical companies. Anyway, they are all here, so it's better to pack them up and sell them to him.

Anyway, these discarded prescriptions are also carefully selected by each family, and they are useless waste.

And Pfizer's list of abandoned prescriptions is particularly eye-catching, because there are too many.

It seems that after learning that he likes to collect discarded prescriptions, the company took advantage of it and packed and sent the discarded new drug recipes from the headquarters laboratory and even the laboratories of all acquired and merged pharmaceutical companies.

There must be some hard work and contribution from Andre.

It is indeed the number one pharmaceutical company in the universe.

What is a multinational pharmaceutical giant!

This is!

There are hundreds of discarded prescriptions!

That's it all packed up.

Although the types are very small, there are even over-the-counter prescriptions such as skin itching, cough medicine, and eye drops.

But Wei Kang didn't care, he just wanted to hug Dr. Andre and thank him for his assist.

It's so sweet!